Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma

Name: Dr. Karmali on FDA Approval of KTE-C19 in Non-Hodgkin Lymphoma
Uploaded: 2017-10-19T01:51:00.000Z
Description: Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

October 18, 2017

Reem Karmali, MD

Video

Reem Karmali, MD, assistant professor of medicine (hematology and oncology), Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.

Reem Karmali, MD, assistant professor of medicine (hematology and oncology, Feinberg School of Medicine, Northwestern University, discusses the FDA approval of axicabtagene ciloleucel (Yescarta; KTE-C19; axi-cel) for the treatment of patients with non-Hodgkin lymphoma.